首页 > 最新文献

Pulmonary Medicine最新文献

英文 中文
Relation of Changes in PEF and FEV1 During Salbutamol-Induced Bronchodilation After Methacholine Challenge Test. 沙丁胺醇致支气管扩张后乙酰胆碱激发试验PEF和FEV1变化的关系。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2025-07-07 eCollection Date: 2025-01-01 DOI: 10.1155/pm/7675935
Leon L Csonka, Antti Tikkakoski, Liisa Vuotari, Jussi Karjalainen, Lauri Lehtimäki

Asthma diagnosis can be confirmed by observing significant bronchodilator response (BDR) through peak expiratory flow (PEF) at home or forced expiratory volume in 1 s (FEV1) via spirometry in a clinical setting. We aimed to use the administration of salbutamol after a methacholine challenge test as a model of bronchodilation to study how accurately the change in PEF predicts improvement in lung function, as defined by an increase in FEV1. We analyzed 869 adult patients who were administered salbutamol after a methacholine challenge. To compare relative changes in PEF and FEV1 during bronchodilation, we used regression analysis and constructed a Bland and Altman plot. ROC analysis, sensitivity, specificity, positive and negative predictive values, and kappa coefficient assessed how precisely increases in PEF detected a 12% and 0.2-L improvement in FEV1. The average relative increase in FEV1 was significantly greater than that in PEF. The area under the curve in the ROC analysis was 0.844 for PEF change to detect a 12% and 0.2-L increase in FEV1. The kappa values for changes in PEF and FEV1 ranged from fair to moderate. BDR detected by the recommended 15% and 60 L/min cut-off for PEF identified less than half of true positives, while a 10% cut-off correctly identified close to 75% of them. PEF increase is not a reliable measure of BDR in comparison to FEV1 increase, and a 10% improvement in PEF was the least inaccurate cut-off. Substituting the PEF meter with a handheld spirometer should be further investigated for asthma home monitoring.

哮喘诊断可以通过在家中通过呼气峰流量(PEF)或在临床环境中通过肺活量测定法观察1 s内用力呼气量(FEV1)观察明显的支气管扩张剂反应(BDR)来证实。我们的目的是在甲胆碱激发试验后使用沙丁胺醇作为支气管扩张的模型,研究PEF的变化预测肺功能改善的准确性(由FEV1增加定义)。我们分析了869例在甲胆碱刺激后给予沙丁胺醇的成年患者。为了比较支气管扩张期间PEF和FEV1的相对变化,我们使用回归分析并构建Bland和Altman图。ROC分析、敏感性、特异性、阳性和阴性预测值以及kappa系数评估了PEF增加对FEV1改善12%和0.2 l的准确性。FEV1的平均相对增幅明显大于PEF。在ROC分析中,PEF变化检测到FEV1增加12%和0.2 l的曲线下面积为0.844。PEF和FEV1变化的kappa值范围从一般到中等。推荐的PEF临界值为15%和60 L/min时,检测到的BDR识别出的真阳性不到一半,而10%的临界值正确识别出了近75%的真阳性。与FEV1增加相比,PEF增加并不是衡量BDR的可靠指标,PEF改善10%是最不准确的截止值。应进一步研究用手持式肺活量计代替PEF计用于哮喘家庭监测。
{"title":"Relation of Changes in PEF and FEV<sub>1</sub> During Salbutamol-Induced Bronchodilation After Methacholine Challenge Test.","authors":"Leon L Csonka, Antti Tikkakoski, Liisa Vuotari, Jussi Karjalainen, Lauri Lehtimäki","doi":"10.1155/pm/7675935","DOIUrl":"10.1155/pm/7675935","url":null,"abstract":"<p><p>Asthma diagnosis can be confirmed by observing significant bronchodilator response (BDR) through peak expiratory flow (PEF) at home or forced expiratory volume in 1 s (FEV<sub>1</sub>) via spirometry in a clinical setting. We aimed to use the administration of salbutamol after a methacholine challenge test as a model of bronchodilation to study how accurately the change in PEF predicts improvement in lung function, as defined by an increase in FEV<sub>1</sub>. We analyzed 869 adult patients who were administered salbutamol after a methacholine challenge. To compare relative changes in PEF and FEV<sub>1</sub> during bronchodilation, we used regression analysis and constructed a Bland and Altman plot. ROC analysis, sensitivity, specificity, positive and negative predictive values, and kappa coefficient assessed how precisely increases in PEF detected a 12% and 0.2-L improvement in FEV<sub>1</sub>. The average relative increase in FEV<sub>1</sub> was significantly greater than that in PEF. The area under the curve in the ROC analysis was 0.844 for PEF change to detect a 12% and 0.2-L increase in FEV<sub>1</sub>. The kappa values for changes in PEF and FEV<sub>1</sub> ranged from fair to moderate. BDR detected by the recommended 15% and 60 L/min cut-off for PEF identified less than half of true positives, while a 10% cut-off correctly identified close to 75% of them. PEF increase is not a reliable measure of BDR in comparison to FEV<sub>1</sub> increase, and a 10% improvement in PEF was the least inaccurate cut-off. Substituting the PEF meter with a handheld spirometer should be further investigated for asthma home monitoring.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2025 ","pages":"7675935"},"PeriodicalIF":2.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Deep Convolutional Neural Network Model for Lung Disease Detection Using Chest X-Ray Imaging. 胸部x线影像肺部疾病检测的深度卷积神经网络模型。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI: 10.1155/pm/6614016
Samia Dardouri

Lung diseases, including pneumonia and COVID-19, are prevalent globally, necessitating early diagnosis for effective treatment. Medical imaging is widely regarded as an effective method for detecting lung diseases. Numerous researchers have dedicated their efforts to developing advanced detection techniques, significantly contributing to the prevention and management of these conditions. Despite advancements in imaging diagnostic methods, chest radiographs remain pivotal due to their cost-effectiveness and rapid results. This study proposes an automated system for detecting multiple lung diseases in x-ray and CT scans using a customized convolutional neural network (CNN) alongside pretrained models and an image enhancement approach. The dataset used comprises 6400 images sourced from Kaggle, categorized into three classes: pneumonia, COVID-19, and normal. To address dataset imbalance, data augmentation techniques were applied. The model includes preprocessing and classification stages, achieving high performance metrics: 96% precision, 95.33% recall, 95.66% F1-score, and 97.24% accuracy, highlighting its effectiveness compared to other deep learning models.

包括肺炎和COVID-19在内的肺部疾病在全球普遍存在,需要及早诊断以进行有效治疗。医学影像学被广泛认为是检测肺部疾病的有效方法。许多研究人员致力于开发先进的检测技术,为这些疾病的预防和管理做出了重大贡献。尽管影像诊断方法取得了进步,但胸部x线片由于其成本效益和快速结果而仍然至关重要。本研究提出了一种自动化系统,用于在x射线和CT扫描中检测多种肺部疾病,该系统使用定制的卷积神经网络(CNN)以及预训练模型和图像增强方法。使用的数据集包括来自Kaggle的6400张图像,分为三类:肺炎、COVID-19和正常。为了解决数据不平衡问题,采用了数据增强技术。该模型包括预处理和分类阶段,实现了较高的性能指标:96%的准确率,95.33%的召回率,95.66%的f1得分和97.24%的准确率,与其他深度学习模型相比,突出了其有效性。
{"title":"A Deep Convolutional Neural Network Model for Lung Disease Detection Using Chest X-Ray Imaging.","authors":"Samia Dardouri","doi":"10.1155/pm/6614016","DOIUrl":"10.1155/pm/6614016","url":null,"abstract":"<p><p>Lung diseases, including pneumonia and COVID-19, are prevalent globally, necessitating early diagnosis for effective treatment. Medical imaging is widely regarded as an effective method for detecting lung diseases. Numerous researchers have dedicated their efforts to developing advanced detection techniques, significantly contributing to the prevention and management of these conditions. Despite advancements in imaging diagnostic methods, chest radiographs remain pivotal due to their cost-effectiveness and rapid results. This study proposes an automated system for detecting multiple lung diseases in x-ray and CT scans using a customized convolutional neural network (CNN) alongside pretrained models and an image enhancement approach. The dataset used comprises 6400 images sourced from Kaggle, categorized into three classes: pneumonia, COVID-19, and normal. To address dataset imbalance, data augmentation techniques were applied. The model includes preprocessing and classification stages, achieving high performance metrics: 96% precision, 95.33% recall, 95.66% <i>F</i>1-score, and 97.24% accuracy, highlighting its effectiveness compared to other deep learning models.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2025 ","pages":"6614016"},"PeriodicalIF":2.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients. 万古霉素监测治疗成人囊性纤维化患者急性肺加重。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2025-05-28 eCollection Date: 2025-01-01 DOI: 10.1155/pm/5683225
Darrell Smith, James Sanders, Marguerite Monogue

Background: Therapeutic drug monitoring (TDM) for vancomycin (VAN) in adult people with cystic fibrosis (pwCF) historically has utilized trough concentrations. Recent VAN TDM guidelines recommend area under the curve (AUC) monitoring to reduce the risk of acute kidney injury (AKI), despite limited evidence to support this practice in adult pwCF. Methods: This single-center, retrospective, observational cohort study included 143 adult pwCF admitted from July 1, 2017, to July 1, 2022, with an acute pulmonary exacerbation that received VAN for at least 72 h with available VAN plasma concentrations for TDM for AUC (n = 39) or trough monitoring (n = 104). Eligible patients with multiple hospital admissions during the study period were incorporated as separate encounters. The primary outcome was the incidence of AKI. Results: Receipt of concurrent nephrotoxins was more common in the AUC cohort than in the trough cohort (97% vs. 81%, p = 0.01), but the rate of AKI was similar (7.7% vs. 10.6%, p = 0.76). AUC monitoring was associated with earlier achievement of TDM goal (median 0 days (IQR 0-2) vs. 2 days (IQR 0-4), p < 0.01), lower total daily doses (34.8 mg/kg/day (IQR 27.6-49) vs. 57.5 mg/kg/day (IQR 43.9-68.6), p < 0.01), and fewer regimen changes (median 1 change (IQR 0-2) vs. 2 changes (IQR 1-3), p < 0.01). In patients with MRSA, pulmonary function recovery, readmission, and mortality were similar. Conclusion: In adult pwCF, the incidence of AKI was similar between AUC and trough monitoring cohorts; however, AUC monitoring achieved therapeutic targets sooner with fewer regimen modifications without significantly increasing the number of concentrations compared to trough monitoring.

背景:成人囊性纤维化(pwCF)患者万古霉素(VAN)的治疗药物监测(TDM)历来使用谷浓度。最近的VAN TDM指南推荐曲线下面积(AUC)监测来降低急性肾损伤(AKI)的风险,尽管在成人pwCF中支持这种做法的证据有限。方法:这项单中心、回顾性、观察性队列研究纳入了2017年7月1日至2022年7月1日收治的143例成年pwCF患者,这些患者急性肺恶化接受VAN治疗至少72小时,并伴有AUC TDM可用VAN血浆浓度(n = 39)或槽监测(n = 104)。在研究期间多次住院的符合条件的患者被纳入单独的接触。主要终点是AKI的发生率。结果:AUC组并发肾毒素比低谷组更常见(97%对81%,p = 0.01),但AKI发生率相似(7.7%对10.6%,p = 0.76)。AUC监测与TDM目标的早期实现(中位0天(IQR 0-2) vs. 2天(IQR 0-4), p < 0.01),较低的总日剂量(34.8 mg/kg/天(IQR 27.6-49) vs. 57.5 mg/kg/天(IQR 43.9-68.6), p < 0.01),较少的方案变化(中位1次变化(IQR 0-2) vs. 2次变化(IQR 1-3), p < 0.01)相关。在MRSA患者中,肺功能恢复、再入院和死亡率相似。结论:在成人pwCF中,AUC组和低谷监测组的AKI发生率相似;然而,与低谷监测相比,AUC监测更快地实现了治疗目标,较少的方案修改,而没有显著增加浓度的数量。
{"title":"Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients.","authors":"Darrell Smith, James Sanders, Marguerite Monogue","doi":"10.1155/pm/5683225","DOIUrl":"10.1155/pm/5683225","url":null,"abstract":"<p><p><b>Background:</b> Therapeutic drug monitoring (TDM) for vancomycin (VAN) in adult people with cystic fibrosis (pwCF) historically has utilized trough concentrations. Recent VAN TDM guidelines recommend area under the curve (AUC) monitoring to reduce the risk of acute kidney injury (AKI), despite limited evidence to support this practice in adult pwCF. <b>Methods:</b> This single-center, retrospective, observational cohort study included 143 adult pwCF admitted from July 1, 2017, to July 1, 2022, with an acute pulmonary exacerbation that received VAN for at least 72 h with available VAN plasma concentrations for TDM for AUC (<i>n</i> = 39) or trough monitoring (<i>n</i> = 104). Eligible patients with multiple hospital admissions during the study period were incorporated as separate encounters. The primary outcome was the incidence of AKI. <b>Results:</b> Receipt of concurrent nephrotoxins was more common in the AUC cohort than in the trough cohort (97% vs. 81%, <i>p</i> = 0.01), but the rate of AKI was similar (7.7% vs. 10.6%, <i>p</i> = 0.76). AUC monitoring was associated with earlier achievement of TDM goal (median 0 days (IQR 0-2) vs. 2 days (IQR 0-4), <i>p</i> < 0.01), lower total daily doses (34.8 mg/kg/day (IQR 27.6-49) vs. 57.5 mg/kg/day (IQR 43.9-68.6), <i>p</i> < 0.01), and fewer regimen changes (median 1 change (IQR 0-2) vs. 2 changes (IQR 1-3), <i>p</i> < 0.01). In patients with MRSA, pulmonary function recovery, readmission, and mortality were similar. <b>Conclusion:</b> In adult pwCF, the incidence of AKI was similar between AUC and trough monitoring cohorts; however, AUC monitoring achieved therapeutic targets sooner with fewer regimen modifications without significantly increasing the number of concentrations compared to trough monitoring.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2025 ","pages":"5683225"},"PeriodicalIF":2.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Regulatory T Cells in Chronic Obstructive Pulmonary Disease. 调节性T细胞在慢性阻塞性肺疾病中的作用
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI: 10.1155/pm/5048054
Meghashree Sampath, Geetanjali Bade, Randeep Guleria, Anant Mohan, Sudip Sen, Anjana Talwar

Background: Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder characterized by poorly reversible airway obstruction. COPD being an inflammatory disorder has been proposed to have an imbalance between proinflammatory and anti-inflammatory factors. Regulatory T cells (Tregs) being a negative regulator of immune response have been observed to play an important role in other inflammatory diseases as well as animal models of inflammation. Objective: This study is aimed at assessing the suppressive functions of circulatory Tregs and examining the inductive capacity of naive CD4+ T cells to generate induced Tregs. Methods: The study was conducted in 20 COPD patients (smokers n = 10; reformed smokers n = 10) and 20 age-matched healthy controls (smokers n = 10; nonsmokers n = 10). Peripheral blood mononuclear cells were isolated from blood using Ficoll density gradient separation. The suppressive functions were evaluated by assessing the proliferation of T responder cells (CD4+CD25-) in the presence of circulatory Tregs (CD4+CD25+) under polyclonal stimulation. In addition, cytokine-mediated suppression was assessed in the culture supernatants of the suppression assay. Inductive capacity was assessed by stimulating naive CD4+ T cells to generate iTregs in the presence of anti-CD3, IL-2, and TGF-β1. Results: The percent suppression of T responder cells by Tregs was significantly lower in COPD smokers (p = 0.03) and COPD reformed smokers (p = 0.04) as compared to control smokers. On the assessment of cytokine-mediated suppression, significantly reduced IL-2 in COPD S as compared to COPD RS (p < 0.05) and reduced IL-10 and TGFß1 in COPD S as compared to CNS (p < 0.05) and CS (p < 0.05) was observed in the culture supernatants of suppression assay. In addition, a significantly higher frequency of iTregs with phenotype CD4+CD25+CD45RA+CD127- was observed in COPD S as compared to COPD RS (p < 0.01). Discussion: Characteristics changes were observed in patients with COPD. The compromised Tregs function, despite the increase in systemic inflammation, suggests a potential role of these cells in the pathogenesis of the disease.

背景:慢性阻塞性肺疾病(COPD)是一种以可逆性较差的气道阻塞为特征的进行性肺部疾病。慢性阻塞性肺病是一种炎症性疾病,其促炎因子和抗炎因子之间存在不平衡。调节性T细胞(Regulatory T cells, Tregs)作为免疫反应的负调节因子,在其他炎症性疾病和炎症动物模型中也发挥着重要作用。目的:本研究旨在评估循环Tregs的抑制功能,并检测初始CD4+ T细胞诱导产生诱导Tregs的能力。方法:研究对象为20例COPD患者(吸烟者10例;戒烟者n = 10)和20名年龄匹配的健康对照者(吸烟者n = 10;非吸烟者n = 10)。采用Ficoll密度梯度分离法分离外周血单个核细胞。通过评估T反应细胞(CD4+CD25-)在循环Tregs (CD4+CD25+)存在下在多克隆刺激下的增殖来评估其抑制功能。此外,在抑制实验的培养上清中评估细胞因子介导的抑制。通过刺激初始CD4+ T细胞在抗cd3、IL-2和TGF-β1存在下产生iTregs来评估诱导能力。结果:与对照组相比,COPD吸烟者(p = 0.03)和COPD改造吸烟者(p = 0.04)中Tregs对T反应细胞的抑制百分比显著降低。在细胞因子介导的抑制评估中,抑制实验培养上清中观察到COPD S中IL-2较COPD RS显著降低(p < 0.05), COPD S中IL-10和TGFß1较CNS显著降低(p < 0.05), CS显著降低(p < 0.05)。此外,与COPD RS相比,COPD S中CD4+CD25+CD45RA+CD127-表型的iTregs频率显著更高(p < 0.01)。讨论:观察COPD患者的特征变化。尽管全身炎症增加,但Tregs功能受损表明这些细胞在疾病发病机制中的潜在作用。
{"title":"Role of Regulatory T Cells in Chronic Obstructive Pulmonary Disease.","authors":"Meghashree Sampath, Geetanjali Bade, Randeep Guleria, Anant Mohan, Sudip Sen, Anjana Talwar","doi":"10.1155/pm/5048054","DOIUrl":"https://doi.org/10.1155/pm/5048054","url":null,"abstract":"<p><p><b>Background:</b> Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder characterized by poorly reversible airway obstruction. COPD being an inflammatory disorder has been proposed to have an imbalance between proinflammatory and anti-inflammatory factors. Regulatory T cells (Tregs) being a negative regulator of immune response have been observed to play an important role in other inflammatory diseases as well as animal models of inflammation. <b>Objective</b>: This study is aimed at assessing the suppressive functions of circulatory Tregs and examining the inductive capacity of naive CD4+ T cells to generate induced Tregs. <b>Methods:</b> The study was conducted in 20 COPD patients (smokers <i>n</i> = 10; reformed smokers <i>n</i> = 10) and 20 age-matched healthy controls (smokers <i>n</i> = 10; nonsmokers <i>n</i> = 10). Peripheral blood mononuclear cells were isolated from blood using Ficoll density gradient separation. The suppressive functions were evaluated by assessing the proliferation of T responder cells (CD4+CD25-) in the presence of circulatory Tregs (CD4+CD25+) under polyclonal stimulation. In addition, cytokine-mediated suppression was assessed in the culture supernatants of the suppression assay. Inductive capacity was assessed by stimulating naive CD4+ T cells to generate iTregs in the presence of anti-CD3, IL-2, and TGF-<i>β</i>1. <b>Results:</b> The percent suppression of T responder cells by Tregs was significantly lower in COPD smokers (<i>p</i> = 0.03) and COPD reformed smokers (<i>p</i> = 0.04) as compared to control smokers. On the assessment of cytokine-mediated suppression, significantly reduced IL-2 in COPD S as compared to COPD RS (<i>p</i> < 0.05) and reduced IL-10 and TGFß1 in COPD S as compared to CNS (<i>p</i> < 0.05) and CS (<i>p</i> < 0.05) was observed in the culture supernatants of suppression assay. In addition, a significantly higher frequency of iTregs with phenotype CD4+CD25+CD45RA+CD127- was observed in COPD S as compared to COPD RS (<i>p</i> < 0.01). <b>Discussion:</b> Characteristics changes were observed in patients with COPD. The compromised Tregs function, despite the increase in systemic inflammation, suggests a potential role of these cells in the pathogenesis of the disease.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2025 ","pages":"5048054"},"PeriodicalIF":2.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Lung Volume Recruitment Technique in Patients With Chronic Respiratory Disease Among Brazilian Health Professionals. 巴西卫生专业人员在慢性呼吸系统疾病患者中肺容量增加技术的应用
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2025-01-10 eCollection Date: 2025-01-01 DOI: 10.1155/pm/4073171
Robert de Melo, Livia Alcantara, Max Sarmet, Nicole L Sheers, David J Berlowitz, Vinicius Maldaner

Background: Lung volume recruitment (LVR) is a stacked-breath assisted inflation technique in which consecutive insufflations are delivered, without exhaling in between, until the maximum tolerable inflation capacity is reached. Although LVR is recommended in some neuromuscular disease guidelines, there is little information detailing when and how allied health professionals (AHPs) prescribe LVR. Objective: This study is aimed at describing the use of LVR in practice across Brazil. Methods: A cross-sectional e-survey (Sep-Nov 2023) explored LVR practices among qualified clinical or home care AHPs in Brazil. It gathered participant data on geographical region, profession, and experience. It delved into LVR specifics: clinical population and indications for use, prescription (frequency, dosage, and interfaces), related side effects, outcomes assessed, and combined therapies. Results were presented descriptively. Results: One hundred two surveys (74 physical therapists (PTs) and 28 speech and language pathologists (SLPs)) from diverse locations were collected. LVR was predominantly prescribed for adults (57%), with the most common diagnosis being amyotrophic lateral sclerosis (84%). Changes in peak cough flow and vital capacity were the most common reasons for LVR prescription. Maximal insufflation capacity was reportedly measured by 58% of PTs and 22% of SLPs. Chest wall soreness and discomfort were the most common side effects, and many respondents did not provide warnings about potential side effects (42% PTs and 50% SLPs). The study highlighted common use of other respiratory therapy devices alongside LVR. Conclusion: LVR is available in routine clinical and home care settings in Brazil. There is a lack of standardization regarding indications, prescription, and outcome measures among PTs and SLPs in Brazil. Clear recommendations and guidelines are needed to standardize these parameters, enabling more objective data and facilitating comparisons between centers.

背景:肺容量补充(LVR)是一种叠加呼吸辅助充气技术,其中连续充气,中间不呼气,直到达到最大可容忍的充气能力。虽然LVR在一些神经肌肉疾病指南中被推荐,但很少有信息详细说明何时以及如何联合卫生专业人员(ahp)开LVR。目的:本研究旨在描述LVR在巴西各地的实践使用。方法:一项横断面电子调查(2023年9月至11月)探讨了巴西合格临床或家庭护理ahp的LVR实践。它收集了参与者的地理区域、职业和经验数据。它深入研究了LVR的具体情况:临床人群和使用适应症、处方(频率、剂量和界面)、相关副作用、评估的结果和联合治疗。结果是描述性的。结果:收集了来自不同地区的物理治疗师(74名)和语言病理学家(28名)共102份问卷。LVR主要用于成人(57%),最常见的诊断是肌萎缩侧索硬化症(84%)。咳嗽高峰流量和肺活量的变化是LVR处方最常见的原因。据报道,58%的PTs和22%的slp测量了最大充气能力。胸壁疼痛和不适是最常见的副作用,许多受访者没有提供潜在副作用的警告(42%的PTs和50%的slp)。该研究强调了除LVR外其他呼吸治疗设备的普遍使用。结论:LVR在巴西的常规临床和家庭护理环境中是可行的。在巴西,PTs和slp之间缺乏关于适应症、处方和结果测量的标准化。需要明确的建议和指导方针来规范这些参数,使数据更加客观,并促进中心之间的比较。
{"title":"Use of Lung Volume Recruitment Technique in Patients With Chronic Respiratory Disease Among Brazilian Health Professionals.","authors":"Robert de Melo, Livia Alcantara, Max Sarmet, Nicole L Sheers, David J Berlowitz, Vinicius Maldaner","doi":"10.1155/pm/4073171","DOIUrl":"10.1155/pm/4073171","url":null,"abstract":"<p><p><b>Background:</b> Lung volume recruitment (LVR) is a stacked-breath assisted inflation technique in which consecutive insufflations are delivered, without exhaling in between, until the maximum tolerable inflation capacity is reached. Although LVR is recommended in some neuromuscular disease guidelines, there is little information detailing when and how allied health professionals (AHPs) prescribe LVR. <b>Objective:</b> This study is aimed at describing the use of LVR in practice across Brazil. <b>Methods:</b> A cross-sectional e-survey (Sep-Nov 2023) explored LVR practices among qualified clinical or home care AHPs in Brazil. It gathered participant data on geographical region, profession, and experience. It delved into LVR specifics: clinical population and indications for use, prescription (frequency, dosage, and interfaces), related side effects, outcomes assessed, and combined therapies. Results were presented descriptively. <b>Results:</b> One hundred two surveys (74 physical therapists (PTs) and 28 speech and language pathologists (SLPs)) from diverse locations were collected. LVR was predominantly prescribed for adults (57%), with the most common diagnosis being amyotrophic lateral sclerosis (84%). Changes in peak cough flow and vital capacity were the most common reasons for LVR prescription. Maximal insufflation capacity was reportedly measured by 58% of PTs and 22% of SLPs. Chest wall soreness and discomfort were the most common side effects, and many respondents did not provide warnings about potential side effects (42% PTs and 50% SLPs). The study highlighted common use of other respiratory therapy devices alongside LVR. <b>Conclusion:</b> LVR is available in routine clinical and home care settings in Brazil. There is a lack of standardization regarding indications, prescription, and outcome measures among PTs and SLPs in Brazil. Clear recommendations and guidelines are needed to standardize these parameters, enabling more objective data and facilitating comparisons between centers.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2025 ","pages":"4073171"},"PeriodicalIF":2.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Trends of Artificial Intelligence in Lung Cancer: A Combined Approach of Analysis With Latent Dirichlet Allocation and HJ-Biplot Statistical Methods. 人工智能在肺癌中的研究趋势:潜在Dirichlet分配与HJ-Biplot统计方法的联合分析。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2024-12-04 eCollection Date: 2024-01-01 DOI: 10.1155/pm/5911646
Javier De La Hoz-M, Karime Montes-Escobar, Viorkis Pérez-Ortiz

Lung cancer (LC) remains one of the leading causes of cancer-related mortality worldwide. With recent technological advances, artificial intelligence (AI) has begun to play a crucial role in improving diagnostic and treatment methods. It is crucial to understand how AI has integrated into LC research and to identify the main areas of focus. The aim of the study was to provide an updated insight into the role of AI in LC research, analyzing evolving topics, geographical distribution, and contributions to journals. The study explores research trends in AI applied to LC through a novel approach combining latent Dirichlet allocation (LDA) topic modeling with the HJ-Biplot statistical technique. A growing interest in AI applications in LC oncology was observed, reflected in a significant increase in publications, especially after 2017, coinciding with the availability of computing resources. Frontiers in Oncology leads in publishing AI-related LC research, reflecting rigorous investigation in the field. Geographically, China and the United States lead in contributions, attributed to significant investment in R&D and corporate sector involvement. LDA analysis highlights key research areas such as pulmonary nodule detection, patient prognosis prediction, and clinical decision support systems, demonstrating the impact of AI in improving LC outcomes. DL and AI emerge as prominent trends, focusing on radiomics and feature selection, promising better decision-making in LC care. The increase in AI-driven research covers various topics, including data analysis methodologies, tumor characterization, and predictive methods, indicating a concerted effort to advance LC research. HJ-Biplot visualization reveals thematic clustering, illustrating temporal and geographical associations and highlighting the influence of high-impact journals and countries with advanced research capabilities. This multivariate approach offers insights into global collaboration dynamics and specialization, emphasizing the evolving role of AI in LC research and diagnosis.

肺癌(LC)仍然是全球癌症相关死亡的主要原因之一。随着近年来的技术进步,人工智能(AI)开始在改善诊断和治疗方法方面发挥关键作用。了解人工智能如何融入LC研究并确定主要关注领域至关重要。这项研究的目的是为人工智能在LC研究中的作用提供最新的见解,分析不断发展的主题、地理分布和对期刊的贡献。本研究通过将潜在狄利克雷分配(latent Dirichlet allocation, LDA)主题建模与HJ-Biplot统计技术相结合的新方法,探讨了人工智能应用于LC的研究趋势。人们对LC肿瘤学中人工智能应用的兴趣日益浓厚,这反映在出版物的显著增加上,特别是在2017年之后,与计算资源的可用性相一致。《肿瘤学前沿》在发表人工智能相关LC研究方面处于领先地位,反映了该领域的严谨研究。从地理上看,中国和美国在贡献方面领先,这归因于在研发方面的大量投资和企业部门的参与。LDA分析强调了肺结节检测、患者预后预测和临床决策支持系统等关键研究领域,展示了人工智能在改善LC预后方面的影响。DL和AI成为突出的趋势,专注于放射组学和特征选择,有望在LC护理中做出更好的决策。人工智能驱动研究的增加涵盖了各种主题,包括数据分析方法、肿瘤表征和预测方法,表明了推进LC研究的一致努力。HJ-Biplot可视化显示专题聚类,说明时间和地理关联,突出高影响力期刊和具有先进研究能力的国家的影响。这种多变量方法提供了对全球协作动态和专业化的见解,强调了人工智能在LC研究和诊断中的不断发展的作用。
{"title":"Research Trends of Artificial Intelligence in Lung Cancer: A Combined Approach of Analysis With Latent Dirichlet Allocation and HJ-Biplot Statistical Methods.","authors":"Javier De La Hoz-M, Karime Montes-Escobar, Viorkis Pérez-Ortiz","doi":"10.1155/pm/5911646","DOIUrl":"10.1155/pm/5911646","url":null,"abstract":"<p><p>Lung cancer (LC) remains one of the leading causes of cancer-related mortality worldwide. With recent technological advances, artificial intelligence (AI) has begun to play a crucial role in improving diagnostic and treatment methods. It is crucial to understand how AI has integrated into LC research and to identify the main areas of focus. The aim of the study was to provide an updated insight into the role of AI in LC research, analyzing evolving topics, geographical distribution, and contributions to journals. The study explores research trends in AI applied to LC through a novel approach combining latent Dirichlet allocation (LDA) topic modeling with the HJ-Biplot statistical technique. A growing interest in AI applications in LC oncology was observed, reflected in a significant increase in publications, especially after 2017, coinciding with the availability of computing resources. <i>Frontiers in Oncology</i> leads in publishing AI-related LC research, reflecting rigorous investigation in the field. Geographically, China and the United States lead in contributions, attributed to significant investment in R&D and corporate sector involvement. LDA analysis highlights key research areas such as pulmonary nodule detection, patient prognosis prediction, and clinical decision support systems, demonstrating the impact of AI in improving LC outcomes. DL and AI emerge as prominent trends, focusing on radiomics and feature selection, promising better decision-making in LC care. The increase in AI-driven research covers various topics, including data analysis methodologies, tumor characterization, and predictive methods, indicating a concerted effort to advance LC research. HJ-Biplot visualization reveals thematic clustering, illustrating temporal and geographical associations and highlighting the influence of high-impact journals and countries with advanced research capabilities. This multivariate approach offers insights into global collaboration dynamics and specialization, emphasizing the evolving role of AI in LC research and diagnosis.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2024 ","pages":"5911646"},"PeriodicalIF":2.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practice Variations in the Diagnosis and Treatment of Pulmonary Embolism. 肺栓塞诊断和治疗的实践差异。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2024-11-04 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6633148
Devesh Thakkar, Frances Garden, John Nguyen, Brenda Ta, Sikandar Hussaini, Claudia C Dobler

Venous thromboembolism is responsible for a significant burden of disease worldwide. Despite the publication of multiple international guidelines, anecdotal evidence suggests significant clinical variation exists in the diagnostic and management pathways of pulmonary embolism (PE). We conducted a retrospective cohort study using electronic medical records to examine clinical variation in patients admitted to a tertiary referral center in Australia with a diagnosis of PE between November 2018 and January 2020. Three hundred cases met the inclusion criteria; we found variation in rates of compression ultrasonography, acute investigation of the right ventricle, and planning of repeat imaging at specialist follow-up. Guidelines do not address the use of compression ultrasonography in already diagnosed PE, are conflicting in their recommendation for acute investigation of the right ventricle, and recommend repeat imaging only if there are persistent symptoms at the time of specialist follow-up. The variations we found in this study may in part be due to physician preference or due to the paucity of evidence for some of these diagnostic practices. Robust future studies are required to guide the use of these investigations in PE.

静脉血栓栓塞症在全球范围内造成了巨大的疾病负担。尽管发布了多个国际指南,但传闻证据表明,肺栓塞(PE)的诊断和管理路径存在显著的临床差异。我们利用电子病历开展了一项回顾性队列研究,以检查 2018 年 11 月至 2020 年 1 月期间澳大利亚一家三级转诊中心收治的诊断为 PE 的患者的临床差异。300 例病例符合纳入标准;我们发现,在专科随访时,加压超声检查、右心室急性检查和计划重复成像的比例存在差异。指南并未涉及对已确诊的 PE 使用压缩超声波检查的问题,在建议对右心室进行急性检查方面存在冲突,并且仅建议在专科随访时出现持续症状时重复成像。我们在本研究中发现的差异部分可能是由于医生的偏好,也可能是由于其中一些诊断方法缺乏证据。今后需要开展更多的研究,为在 PE 中使用这些检查方法提供指导。
{"title":"Practice Variations in the Diagnosis and Treatment of Pulmonary Embolism.","authors":"Devesh Thakkar, Frances Garden, John Nguyen, Brenda Ta, Sikandar Hussaini, Claudia C Dobler","doi":"10.1155/2024/6633148","DOIUrl":"https://doi.org/10.1155/2024/6633148","url":null,"abstract":"<p><p>Venous thromboembolism is responsible for a significant burden of disease worldwide. Despite the publication of multiple international guidelines, anecdotal evidence suggests significant clinical variation exists in the diagnostic and management pathways of pulmonary embolism (PE). We conducted a retrospective cohort study using electronic medical records to examine clinical variation in patients admitted to a tertiary referral center in Australia with a diagnosis of PE between November 2018 and January 2020. Three hundred cases met the inclusion criteria; we found variation in rates of compression ultrasonography, acute investigation of the right ventricle, and planning of repeat imaging at specialist follow-up. Guidelines do not address the use of compression ultrasonography in already diagnosed PE, are conflicting in their recommendation for acute investigation of the right ventricle, and recommend repeat imaging only if there are persistent symptoms at the time of specialist follow-up. The variations we found in this study may in part be due to physician preference or due to the paucity of evidence for some of these diagnostic practices. Robust future studies are required to guide the use of these investigations in PE.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2024 ","pages":"6633148"},"PeriodicalIF":2.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of COVID-19 Pandemic on Respiratory Syncytial Virus Infection in Children. COVID-19 大流行对儿童呼吸道合胞病毒感染的影响。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2024-10-18 eCollection Date: 2024-01-01 DOI: 10.1155/2024/2131098
Jose Boris Trigueros Montes, Diego Montes, Andrew Miele, Won Baik-Han, Gagan Gulati, Lily Q Lew

Background/Objective: Respiratory syncytial virus (RSV) is a major cause of bronchiolitis in infants and young children. Bronchiolitis, an acute inflammation of the lower respiratory tract, can lead to pneumonia, respiratory failure, and death. We aimed to compare the incidence and severity of RSV infection in children aged 0-60 months before and during the coronavirus disease 2019 (COVID-19) pandemic. Methods: A retrospective chart review was conducted on patients aged 0-60 months who tested positive for RSV between May 1, 2018, and May 31, 2022, in a community hospital in Queens County, New York City, United States. Comparisons were made between seasons 2018-2019 and 2019-2020 as before, and seasons 2020-2021 and 2021-2022 as during the COVID-19 pandemic. Severity of RSV infection was assessed using the Bronchiolitis Severity Score (BSS). Data were analyzed using R software, a p value of < 0.05 was considered statistically significant. Results: The incidence of RSV infection in seasons 2018-2019 and 2019-2020 peaked from mid-October to February, whereas the first season during the COVID-19 pandemic (2020-2021) was truncated with a very low incidence of RSV infection, and season 2021-2022 peaked from September to January, with the highest incidence (37%) and lower frequency of RSV infection at any given point. Patients during the season 2021-2022 were older (H [2, 196.6] = 12.5, p < 0.001, 95% CI = [5.4, 25.6]) and had milder illness (H [2, 187.5] = 7.5, p < 0.01, 95% CI = [2.1, 19.2]). Conclusions: We observed a lower incidence of RSV infection and a lower rate of hospitalization for RSV during the COVID-19 pandemic. The second RSV season during the COVID-19 pandemic began earlier, lasted longer, and had a lower frequency. Older children with milder illnesses were affected most during this season. RSV epidemiology and disease burden were impacted by the COVID-19 pandemic and could have significant ramifications for its prevention and control strategies.

背景/目的:呼吸道合胞病毒(RSV)是导致婴幼儿支气管炎的主要原因。支气管炎是下呼吸道的急性炎症,可导致肺炎、呼吸衰竭和死亡。我们旨在比较 2019 年冠状病毒病(COVID-19)大流行之前和期间 0-60 个月儿童 RSV 感染的发病率和严重程度。研究方法我们对美国纽约市皇后区一家社区医院在2018年5月1日至2022年5月31日期间检测出RSV阳性的0-60个月大的患者进行了回顾性病历审查。将 2018-2019 年和 2019-2020 年这两个季节与之前进行了比较,将 2020-2021 年和 2021-2022 年这两个季节与 COVID-19 大流行期间进行了比较。RSV感染的严重程度采用支气管炎严重程度评分(BSS)进行评估。数据使用 R 软件进行分析,P 值小于 0.05 视为具有统计学意义。结果2018-2019年和2019-2020年两季的RSV感染率在10月中旬至2月达到高峰,而COVID-19大流行期间的第一个季节(2020-2021年)被截断,RSV感染率很低;2021-2022年两季的RSV感染率在9月至1月达到高峰,在任何给定时间点的RSV感染率最高(37%),频率较低。2021-2022 季度的患者年龄较大(H [2, 196.6] = 12.5,P < 0.001,95% CI = [5.4, 25.6]),病情较轻(H [2, 187.5] = 7.5,P < 0.01,95% CI = [2.1, 19.2])。结论我们观察到,在 COVID-19 大流行期间,RSV 感染率较低,RSV 住院率也较低。COVID-19 大流行期间的第二个 RSV 季节开始较早,持续时间较长,频率较低。在这一流行季节,年龄较大、病情较轻的儿童受影响最大。RSV 流行病学和疾病负担受到 COVID-19 大流行的影响,可能对其预防和控制策略产生重大影响。
{"title":"The Impact of COVID-19 Pandemic on Respiratory Syncytial Virus Infection in Children.","authors":"Jose Boris Trigueros Montes, Diego Montes, Andrew Miele, Won Baik-Han, Gagan Gulati, Lily Q Lew","doi":"10.1155/2024/2131098","DOIUrl":"10.1155/2024/2131098","url":null,"abstract":"<p><p><b>Background/Objective:</b> Respiratory syncytial virus (RSV) is a major cause of bronchiolitis in infants and young children. Bronchiolitis, an acute inflammation of the lower respiratory tract, can lead to pneumonia, respiratory failure, and death. We aimed to compare the incidence and severity of RSV infection in children aged 0-60 months before and during the coronavirus disease 2019 (COVID-19) pandemic. <b>Methods:</b> A retrospective chart review was conducted on patients aged 0-60 months who tested positive for RSV between May 1, 2018, and May 31, 2022, in a community hospital in Queens County, New York City, United States. Comparisons were made between seasons 2018-2019 and 2019-2020 as before, and seasons 2020-2021 and 2021-2022 as during the COVID-19 pandemic. Severity of RSV infection was assessed using the Bronchiolitis Severity Score (BSS). Data were analyzed using R software, a <i>p</i> value of < 0.05 was considered statistically significant. <b>Results:</b> The incidence of RSV infection in seasons 2018-2019 and 2019-2020 peaked from mid-October to February, whereas the first season during the COVID-19 pandemic (2020-2021) was truncated with a very low incidence of RSV infection, and season 2021-2022 peaked from September to January, with the highest incidence (37%) and lower frequency of RSV infection at any given point. Patients during the season 2021-2022 were older (<i>H</i> [2, 196.6] = 12.5, <i>p</i> < 0.001, 95% <i>CI</i> = [5.4, 25.6]) and had milder illness (<i>H</i> [2, 187.5] = 7.5, <i>p</i> < 0.01, 95% <i>CI</i> = [2.1, 19.2]). <b>Conclusions:</b> We observed a lower incidence of RSV infection and a lower rate of hospitalization for RSV during the COVID-19 pandemic. The second RSV season during the COVID-19 pandemic began earlier, lasted longer, and had a lower frequency. Older children with milder illnesses were affected most during this season. RSV epidemiology and disease burden were impacted by the COVID-19 pandemic and could have significant ramifications for its prevention and control strategies.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2024 ","pages":"2131098"},"PeriodicalIF":2.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-Task Performance in Individuals With Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-Analysis. 慢性阻塞性肺病患者的双任务表现:带 Meta 分析的系统性综述。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-10 eCollection Date: 2024-01-01 DOI: 10.1155/2024/1230287
Joselyn González Pasten, Jennifer Campos Aguayo, Javiera Aburto, Felipe Araya-Quintanilla, Alejandro Álvarez-Bustos, Juan José Valenzuela-Fuenzalida, Pat G Camp, Walter Sepúlveda-Loyola

Background: Chronic obstructive pulmonary disease (COPD) is characterized by important extrapulmonary alterations that could affect the performance in dual task (DT) (motor and cognitive tasks executed simultaneously), which is defined as DT interference (DTI). Objective: To compare the performance of DT between individuals with COPD and healthy control subjects (HCSs). Methods: The literature search was conducted in seven databases (Medline, Scopus, Web of Science, PEDro, SciELO, LILACS, and Google Scholar) up to December 2023, including studies published in English, Spanish, or Portuguese. Studies with individuals diagnosed with COPD older than 60 years, who were evaluated with any DT assessment, and compared with HCS were included. The quality of the studies was evaluated using the risk of bias in nonrandomized studies of interventions (ROBINS-I). The meta-analysis was performed with JAMOVI software 5.4. The study protocol was registered on PROSPERO (CRD42023435212). Results: From a total of 128 articles, 5 observational studies were selected in this review, involving 252 individuals aged between 60 and 80 years, from France, Italy, Canada, Turkey, and Belgium. Notable DTI was observed in individuals with COPD compared to HCS (standard mean difference [SMD] = 0.91; 95% confidence interval (CI) 0.06-1.75, p = 0.04). Individuals with COPD had impaired gait speed, balance control, muscle strength, and cognitive interference during DT compared to HCS. DT assessment protocols included different combination of motor and cognitive tasks, using functional test, gait analysis, and muscle strength paired with countdown and verbal fluency tasks. Studies presented low (n = 2), moderate (n = 1), and serious (n = 2) overall risk of bias. Conclusion: Older adults diagnosed with COPD exhibited a significant DTI compared to HCSs, which is characterized by poorer physical and cognitive performance during DT execution. These findings highlight the importance of incorporating DT assessments into clinical practice for individuals with COPD.

背景:慢性阻塞性肺疾病(COPD)的特点是重要的肺外改变,可能影响双重任务(DT)(同时执行运动和认知任务)的表现,这被定义为 DT 干扰(DTI)。目的比较慢性阻塞性肺病患者和健康对照受试者(HCSs)的 DT 表现。方法在截至 2023 年 12 月的七个数据库(Medline、Scopus、Web of Science、PEDro、SciELO、LILACS 和 Google Scholar)中进行文献检索,包括以英语、西班牙语或葡萄牙语发表的研究。研究对象包括 60 岁以上确诊为慢性阻塞性肺病的患者,他们接受了任何 DT 评估,并与 HCS 进行了比较。研究质量采用非随机干预研究偏倚风险(ROBINS-I)进行评估。荟萃分析使用 JAMOVI 软件 5.4 进行。研究方案已在 PROSPERO(CRD42023435212)上注册。研究结果本综述从 128 篇文章中选出了 5 项观察性研究,涉及 252 名年龄在 60 至 80 岁之间的患者,他们分别来自法国、意大利、加拿大、土耳其和比利时。与慢性阻塞性肺病患者相比,慢性阻塞性肺病患者的 DTI 显著增加(标准平均差 [SMD] = 0.91;95% 置信区间 (CI) 0.06-1.75,P = 0.04)。与 HCS 相比,慢性阻塞性肺病患者在 DT 过程中的步速、平衡控制、肌肉力量和认知干扰都有所减弱。DT 评估方案包括不同的运动和认知任务组合,使用功能测试、步态分析、肌力与倒计时和语言流畅性任务配对。研究的总体偏倚风险较低(2 项)、中等(1 项)和严重(2 项)。结论与高危人群相比,诊断出慢性阻塞性肺病的老年人表现出明显的 DTI,其特点是在执行 DT 时身体和认知表现较差。这些发现强调了将 DT 评估纳入慢性阻塞性肺病患者临床实践的重要性。
{"title":"Dual-Task Performance in Individuals With Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-Analysis.","authors":"Joselyn González Pasten, Jennifer Campos Aguayo, Javiera Aburto, Felipe Araya-Quintanilla, Alejandro Álvarez-Bustos, Juan José Valenzuela-Fuenzalida, Pat G Camp, Walter Sepúlveda-Loyola","doi":"10.1155/2024/1230287","DOIUrl":"10.1155/2024/1230287","url":null,"abstract":"<p><p><b>Background:</b> Chronic obstructive pulmonary disease (COPD) is characterized by important extrapulmonary alterations that could affect the performance in dual task (DT) (motor and cognitive tasks executed simultaneously), which is defined as DT interference (DTI). <b>Objective:</b> To compare the performance of DT between individuals with COPD and healthy control subjects (HCSs). <b>Methods:</b> The literature search was conducted in seven databases (Medline, Scopus, Web of Science, PEDro, SciELO, LILACS, and Google Scholar) up to December 2023, including studies published in English, Spanish, or Portuguese. Studies with individuals diagnosed with COPD older than 60 years, who were evaluated with any DT assessment, and compared with HCS were included. The quality of the studies was evaluated using the risk of bias in nonrandomized studies of interventions (ROBINS-I). The meta-analysis was performed with JAMOVI software 5.4. The study protocol was registered on PROSPERO (CRD42023435212). <b>Results:</b> From a total of 128 articles, 5 observational studies were selected in this review, involving 252 individuals aged between 60 and 80 years, from France, Italy, Canada, Turkey, and Belgium. Notable DTI was observed in individuals with COPD compared to HCS (standard mean difference [SMD] = 0.91; 95% confidence interval (CI) 0.06-1.75, <i>p</i> = 0.04). Individuals with COPD had impaired gait speed, balance control, muscle strength, and cognitive interference during DT compared to HCS. DT assessment protocols included different combination of motor and cognitive tasks, using functional test, gait analysis, and muscle strength paired with countdown and verbal fluency tasks. Studies presented low (<i>n</i> = 2), moderate (<i>n</i> = 1), and serious (<i>n</i> = 2) overall risk of bias. <b>Conclusion:</b> Older adults diagnosed with COPD exhibited a significant DTI compared to HCSs, which is characterized by poorer physical and cognitive performance during DT execution. These findings highlight the importance of incorporating DT assessments into clinical practice for individuals with COPD.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2024 ","pages":"1230287"},"PeriodicalIF":2.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11330333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. 确定含贝达喹治疗耐药结核病的安全性和有效性:随机临床试验的系统回顾和元分析》。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-09 eCollection Date: 2024-01-01 DOI: 10.1155/2024/5542658
Muhammad Candragupta Jihwaprani, Yipeng Sun, Wahyu Choirur Rizky, Idris Sula, Nazmus Saquib

The risks and benefits of bedaquiline (BDQ) for treatment of drug-resistant tuberculosis (DR-TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceDirect, and SinoMed) were searched. RCTs among DR-TB patients that had a control arm were eligible. The safety endpoints were all-cause mortality and serious adverse effects (SAEs). Efficacy outcomes were sputum culture conversion rate at 8-12 weeks and 24-26 weeks, treatment success, and time to culture conversion. A total of 476 records were screened; 18 met the eligibility criteria. The pooled analysis included 2520 participants (55.8% received BDQ-containing regimens, n = 1408). Pooled safety outcomes showed no significant reduction in all-cause mortality (relative risk [RR] [95%confidence interval (CI)] = 0.94 [0.41-2.20]) or SAEs (RR [95%CI] = 0.91 [0.67-1.23]) in the BDQ-regimen group. Pooled efficacy outcomes showed significantly superior culture conversion rates at 8-12 weeks (RR [95%CI] = 1.35 [1.10-1.65]) and 24-26 weeks (RR [95%CI] = 1.25 [1.15-1.36]), more treatment success (RR [95%CI] = 1.30 [1.17-1.44]), and a 17-day reduction in the time to culture conversion (standardized mean difference [SMD] [95%CI] = -17.46 [-34.82 to -0.11]) in the BDQ-regimen group (reference: non-BDQ regimen). Overall, BDQ regimens showed significant treatment effect against DR-TB but did not reduce mortality or SAEs.

贝达喹啉(BDQ)治疗耐药结核病(DR-TB)的风险和益处尚未得到证实。我们的目的是评估现有随机对照试验(RCT)证明的含贝达喹啉治疗 DR-TB 的安全性和有效性。在本系统综述和荟萃分析中,检索了五个数据库(即 ClinicalTrials.gov、Cochrane CENTRAL、PubMed、ScienceDirect 和 SinoMed)。在 DR-TB 患者中进行的有对照组的 RCT 符合条件。安全性终点为全因死亡率和严重不良反应(SAE)。疗效结局为 8-12 周和 24-26 周的痰培养转换率、治疗成功率和培养转换时间。共筛选出 476 份记录,其中 18 份符合资格标准。汇总分析包括 2520 名参与者(55.8% 接受了含 BDQ 方案,n = 1408)。汇总的安全性结果显示,BDQ方案组的全因死亡率(相对风险[RR][95%置信区间(CI)] = 0.94 [0.41-2.20])或SAE(RR [95%CI] = 0.91 [0.67-1.23])没有显著降低。汇总疗效结果显示,8-12 周(RR [95%CI] = 1.35 [1.10-1.65])和 24-26 周(RR [95%CI] = 1.25 [1.15-1.36])培养转换率明显优于对照组,治疗成功率更高(RR [95%CI] = 1.30 [1.17-1.44]),BDQ方案组(参考:非BDQ方案)的培养转换时间缩短了17天(标准化平均差[SMD] [95%CI] = -17.46 [-34.82 to -0.11])。总体而言,BDQ方案对DR-TB有显著的治疗效果,但并未降低死亡率或SAEs。
{"title":"Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","authors":"Muhammad Candragupta Jihwaprani, Yipeng Sun, Wahyu Choirur Rizky, Idris Sula, Nazmus Saquib","doi":"10.1155/2024/5542658","DOIUrl":"10.1155/2024/5542658","url":null,"abstract":"<p><p>The risks and benefits of bedaquiline (BDQ) for treatment of drug-resistant tuberculosis (DR-TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceDirect, and SinoMed) were searched. RCTs among DR-TB patients that had a control arm were eligible. The safety endpoints were all-cause mortality and serious adverse effects (SAEs). Efficacy outcomes were sputum culture conversion rate at 8-12 weeks and 24-26 weeks, treatment success, and time to culture conversion. A total of 476 records were screened; 18 met the eligibility criteria. The pooled analysis included 2520 participants (55.8% received BDQ-containing regimens, <i>n</i> = 1408). Pooled safety outcomes showed no significant reduction in all-cause mortality (relative risk [RR] [95%confidence interval (CI)] = 0.94 [0.41-2.20]) or SAEs (RR [95%CI] = 0.91 [0.67-1.23]) in the BDQ-regimen group. Pooled efficacy outcomes showed significantly superior culture conversion rates at 8-12 weeks (RR [95%CI] = 1.35 [1.10-1.65]) and 24-26 weeks (RR [95%CI] = 1.25 [1.15-1.36]), more treatment success (RR [95%CI] = 1.30 [1.17-1.44]), and a 17-day reduction in the time to culture conversion (standardized mean difference [SMD] [95%CI] = -17.46 [-34.82 to -0.11]) in the BDQ-regimen group (reference: non-BDQ regimen). Overall, BDQ regimens showed significant treatment effect against DR-TB but did not reduce mortality or SAEs.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2024 ","pages":"5542658"},"PeriodicalIF":2.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pulmonary Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1